Meeting
2016 ASCO Annual Meeting
Updated results: phase I trial of autologous CD19-targeted CAR T cells in patients with residual CLL following initial purine analog-based therapy.
Authors
Mark Blaine Geyer
Memorial Sloan Kettering Cancer Center, New York, NY
Mark Blaine Geyer , Jae Hong Park , Isabelle Riviere , Xiuyan Wang , Terence Purdon , Michel Sadelain , Renier J. Brentjens
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Track
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Sub Track
Chronic Lymphocytic Leukemia (CLL) and Hairy Cell
Clinical Trial Registration Number
NCT01416974
Citation
J Clin Oncol 34, 2016 (suppl; abstr 7526)
DOI
10.1200/JCO.2016.34.15_suppl.7526
Abstract #
7526
Poster Bd #
82
Abstract Disclosures
Similar Posters
Poster
2014 ASCO Annual Meeting
Phase I trial of autologous CD19-targeted CAR-modified t cells as consolidation after purine analog-based first-line therapy in patients with previously untreated CLL.
First Author: Jae Hong Park
Poster
2022 ASCO Gastrointestinal Cancers Symposium
An open, single-center, exploratory clinical trial to evaluate the safety and efficacy of RNA CAR-mesothelin T cells in patients with advanced refractory pancreatic cancer.
First Author: Hui Yang
Poster
2024 ASCO Annual Meeting
A first-in-human phase 1 trial of T cell membrane-anchored tumor targeted IL12 (ATTIL12) -T cell therapy in advanced/metastatic soft tissue and bone sarcoma.
First Author: J. Andrew Livingston
Poster
2024 ASCO Genitourinary Cancers Symposium
Final results of a phase I trial of HERV-E TCR transduced T cells for the treatment of HLA-A*11 patients with metastatic clear cell renal cell carcinoma (mccRCC).
First Author: Rosa Nadal